|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/137 | |
| A61K 31/7042 | |||
| A61P 3/04 | |||
| A61P 3/00 | |||
| A61P 9/00 | |||
| A61P 9/12 | |||
| A61P 13/00 | |||
| A61P 1/16 | |||
| A61P 43/00 |
| (11) | Number of the document | 3349740 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16771043.3 |
| Date of filing the European patent application | 2016-09-13 | |
| (97) | Date of publication of the European application | 2018-07-25 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/051435 |
| Date | 2016-09-13 |
| (87) | Number | WO 2017/048670 |
| Date | 2017-03-23 |
| (30) | Number | Date | Country code |
| 201562218842 P | 2015-09-15 | US | |
| 201662306110 P | 2016-03-10 | US | |
| 201615262038 | 2016-09-12 | US |
| (72) |
ROSENTHAL, Norman R., US
ROTHENBERG, Paul, US
POLIDORI, David C., US
WAYS, Douglas K., US
STEIN, Peter P., US
|
| (73) |
Janssen Pharmaceutica NV,
Turnhoutseweg 30, 2340 Beerse,
BE
|
| (54) | CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR USE IN THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS |
| CO-THERAPY COMPRISING CANAGLIFLOZIN AND PHENTERMINE FOR USE IN THE TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS |